Natural history of nonhuman primates after conjunctival exposure to Ebola virus
R. W. Cross, A. N. Prasad, C. Woolsey, K. N. Agans, V. Borisevich, N. S. Dobias, J. E. Comer, D. J. Deer, J. B. Geisbert, A. Rasmussen, W. I. Lipkin, K. A. Fenton, T. W. Geisbert
Abstract
Transmission of Ebola virus (EBOV) primarily occurs via contact exposure of mucosal surfaces with infected body fluids. Historically, nonhuman primate (NHP) challenge studies have employed intramuscular or small particle aerosol exposure, which are uniformly lethal routes of infection, but mimic worst-case scenarios such as a needlestick. When exposed by more likely routes of natural infection, limited NHP studies have shown delayed onset of disease and reduced mortality. Here we performed a series of systematic natural history studies in cynomolgus macaques with a range of conjunctival exposure doses. Challenge with 10,000 plaque forming units (PFU) of EBOV was uniformly lethal, whereas 5/6 subjects survived low and moderate dose challenges (100 or 500 PFU). Conjunctival challenge resulted in a protracted time-to death. Asymptomatic disease was observed in survivors with limited detection of EBOV replication. Inconsistent seropositivity in survivors may suggest physical or natural immunological barriers are sufficient to prevent widespread viral dissemination.
02 /Specification & Classification
Click any tag to browse matching papers- Organism
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Silent Footprints of Ebolavirus in the Forest: Serological Clues from Wild Non-Human Primates in the Democratic Republic of Congo
Charles Kumakamba, Clément Labarrere, … Oleg Mediannikov·bioRxiv·Mar 9, 2026
- Prior vaccination with the rVSV-ZEBOV vaccine does not interfere with but improves the efficacy of postexposure antibody treatment in nonhuman primates exposed to Ebola virus
R. W. Cross, Z. A. Bornholdt, … T. W. Geisbert·bioRxiv·Apr 1, 2020
- Pathogenesis and natural history of the Bundibugyo species of Orthoebolavirus in nonhuman primates
Karla A. Fenton, Declan D. Pigeaud, … Thomas W. Geisbert·bioRxiv·Aug 12, 2026
- Low-dose VSV-EBOV vaccination provides rapid protection from lethal Ebola virus challenge
Andrea Marzi, Wakako Furuyama, … Heinz Feldmann·bioRxiv·Feb 15, 2026
- Windows of opportunity for Ebola virus infection treatment and vaccination
Vān Kính Nguyễn, Esteban Abelardo Hernandez-Vargas·Scientific ReportsPeer-reviewed·Aug 15, 2017
- Ebola's Hidden Target: Virus Transmission to and Accumulation within Skin
Paige T. Richards, Anthony M. Fleck, … Wendy J. Maury·bioRxiv·Apr 4, 2025